Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure (REE) and hormone levels. Methods: In a randomized controlled GH trial including 47 children with PWS, we assessed 5-day dietary records and dual-energy X-ray absorptiometry for body composition. REE was calculated by Müller's equation, based on fat mass, fat free mass and gender. Results: Baseline energy intake of children with PWS was lower than normal daily energy requirements (p < 0.001), and decreased with age to 50% in prepubertal children. Energy intake in infants [m/f: 11/8; median (interquartile range [IQR]) age 2.7 years (1.5-3.2)] increased after 1 year of GH treatment (p = 0.008); this tended to be higher in the GH group than in the untreated group (p = 0.07). In prepubertal children [m/f: 14/14; median (IQR) age 6.8 years (5.1-8.1)], the increase in energy intake was higher in the GH group, but this was not different compared to the untreated group. REE was not different between the GH group and the untreated group. Increase in energy intake during 2 years of GH treatment was correlated with lower fat percentage standard deviation scores (p = 0.037) and higher adiponectin levels (p = 0.007). Conclusion: Our study demonstrates that parents of children with PWS are very well capable of restricting energy intake up to 50% compared to daily energy requirements for age- and sex-matched healthy children. GH treatment was associated with a slight increase in energy intake, but also improved body composition and adiponectin levels, which suggests a protective effect of GH treatment.

Keywords:
Prader-Willi syndrome, Growth hormone treatment, Dietary management, Body composition
1.
Cassidy SB, Driscoll DJ: Prader-willi syndrome. Eur J Hum Genet 2009;17:3-13.
2.
Vogels A, Van Den Ende J, Keymolen K, Mortier G, Devriendt K, Legius E, Fryns JP: Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet 2004;12:238-240.
3.
Akefeldt A, Gillberg C, Larsson C: Prader-Willi syndrome in a Swedish rural county: epidemiological aspects. Dev Med Child Neurol 1991;33:715-721.
4.
Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M: Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-4197.
5.
Butler JV, Whittington JE, Holland AJ, McAllister CJ, Goldstone AP: The transition between the phenotypes of Prader-Willi syndrome during infancy and early childhood. Dev Med Child Neurol 2010;52:e88-e93.
6.
Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Schroor EJ, Van Alfen AA, Van Leeuwen M, Van Pinxteren-Nagler E, Van Wieringen H, Vreuls RC, Zwaveling-Soonawala N, de Ridder MA, Hokken-Koelega AC: Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab 2013;98:4013-4022.
7.
de Lind van Wijngaarden RF, Siemensma EP, Festen DA, Otten BJ, van Mil EG, Rotteveel J, Odink RJ, Bindels-de Heus GC, van Leeuwen M, Haring DA, Bocca G, Houdijk EC, Hoorweg-Nijman JJ, Vreuls RC, Jira PE, van Trotsenburg AS, Bakker B, Schroor EJ, Pilon JW, Wit JM, Drop SL, Hokken-Koelega AC: Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2009;94:4205-4215.
8.
Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC: Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol 2008;69:443-451.
9.
Carrel AL, Myers SE, Whitman BY, Allen DB: Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581-1585.
10.
Schoeller DA, Levitsky LL, Bandini LG, Dietz WW, Walczak A: Energy expenditure and body composition in Prader-Willi syndrome. Metabolism 1988;37:115-120.
11.
Van Mil EA, Westerterp KR, Gerver WJ, Curfs LM, Schrander-Stumpel CT, Kester AD, Saris WH: Energy expenditure at rest and during sleep in children with Prader-Willi syndrome is explained by body composition. Am J Clin Nutr 2000;71:752-756.
12.
Oosterhof R, Ith M, Trepp R, Christ E, Fluck M: Regulation of whole body energy homeostasis with growth hormone replacement therapy and endurance exercise. Physiol Genomics 2011;43:739-748.
13.
de Lind van Wijngaarden RF, Cianflone K, Gao Y, Leunissen RW, Hokken-Koelega AC: Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. J Clin Endocrinol Metab 2010;95:1758-1766.
14.
Festen DA, van Toorenenbergen A, Duivenvoorden HJ, Hokken-Koelega AC: Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy. J Clin Endocrinol Metab 2007;92:1549-1554.
15.
Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226-228.
16.
Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K: Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003;14:561-566.
17.
Torun B: Energy requirements of children and adolescents. Public Health Nutr 2005;8:968-993.
18.
Boonstra VH, Arends NJ, Stijnen T, Blum WF, Akkerman O, Hokken-Koelega AC: Food intake of children with short stature born small for gestational age before and during a randomized GH trial. Horm Res 2006;65:23-30.
19.
Blissett J, Harris G, Kirk J: Effect of growth hormone therapy on feeding problems and food intake in children with growth disorders. Acta Paediatr 2000;89:644-649.
20.
Galassetti P, Saetrum Opgaard O, Cassidy SB, Pontello A: Nutrient intake and body composition variables in Prader-Willi syndrome - effect of growth hormone supplementation and genetic subtype. J Pediatr Endocrinol Metab 2007;20:491-500.
21.
Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170-179.
22.
NEVO: NEVO Table, Dutch Nutrition Database. Zeist, the Netherlands, 2008.
23.
WHO: Human energy requirements: report of a joint FAO/WHO/UNU expert consultation. Food Nutr Bull 2005;26:166.
24.
Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM: Continuing positive secular growth change in the Netherlands 1955-1997. Pediatr Res 2000;47:316-323.
25.
Gerver WJ, Drayer NM, Schaafsma W: Reference values of anthropometric measurements in Dutch children. The Oosterwolde study. Acta Paediatr Scand 1989;78:307-313.
26.
Gerver WJ, de Bruin R: Body composition in children based on anthropometric data. A presentation of normal values. Eur J Pediatr 1996;155:870-876.
27.
Boot AM, Bouquet J, de Ridder MA, Krenning EP, de Muinck Keizer-Schrama SM: Determinants of body composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents. Am J Clin Nutr 1997;66:232-238.
28.
Müller MJ, Bosy-Westphal A, Klaus S, Kreymann G, Luhrmann PM, Neuhauser-Berthold M, Noack R, Pirke KM, Platte P, Selberg O, Steiniger J: World Health Organization equations have shortcomings for predicting resting energy expenditure in persons from a modern, affluent population: generation of a new reference standard from a retrospective analysis of a German database of resting energy expenditure. Am J Clin Nutr 2004;80:1379-1390.
29.
Hofsteenge GH, Chinapaw MJ, Delemarre-van de Waal HA, Weijs PJ: Validation of predictive equations for resting energy expenditure in obese adolescents. Am J Clin Nutr 2010;91:1244-1254.
30.
Maffeis C, Schutz Y, Zoccante L, Micciolo R, Pinelli L: Meal-induced thermogenesis in lean and obese prepubertal children. Am J Clin Nutr 1993;57:481-485.
31.
Holland AJ, Wong J: Genetically determined obesity in Prader-Willi syndrome: the ethics and legality of treatment. J Med Ethics 1999;25:230-236.
32.
Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, Dykens E, Butler MG, Shuster JJ, Driscoll DJ: Nutritional phases in Prader-Willi syndrome. Am J Med Genet A 2011;155A:1040-1049.
33.
Lindmark M, Trygg K, Giltvedt K, Kolset SO: Nutritient intake of young children with Prader-Willi syndrome. Food Nutr Res 2010;54, DOI: 10.3402/fnr.v54i02112.
34.
Schoeller DA: The energy balance equation: looking back and looking forward are two very different views. Nutr Rev 2009;67:249-254.
35.
Myers SE, Carrel AL, Whitman BY, Allen DB: Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr 2000;137:42-49.
36.
Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, LaFranchi SH: Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab 2003;88:2206-2212.
37.
Van Mil EG, Westerterp KR, Kester AD, Curfs LM, Gerver WJ, Schrander-Stumpel CT, Saris WH: Activity related energy expenditure in children and adolescents with Prader-Willi syndrome. Int J Obes Relat Metab Disord 2000;24:429-434.
38.
Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB: Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet A 2007;143:443-448.
39.
Eiholzer U, l'Allemand D, van der Sluis I, Steinert H, Gasser T, Ellis K: Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy. Horm Res 2000;53:200-206.
40.
Deal CL, Tony M, Hoybye C, Allen DB, Tauber M, Christiansen JS; Growth Hormone in Prader-Willi Syndrome Clinical Care Guidelines Workshop Participants: Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013;98:E1072-E1087.
41.
Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
42.
Zipf WB: Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy. Acta Paediatr Suppl 1999;88:115-117.
43.
Eiholzer U, Stutz K, Weinmann C, Torresani T, Molinari L, Prader A: Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediatr 1998;157:890-893.
44.
Wölfing B, Neumeier M, Buechler C, Aslanidis C, Scholmerich J, Schaffler A: Interfering effects of insulin, growth hormone and glucose on adipokine secretion. Exp Clin Endocrinol Diabetes 2008;116:47-52.
45.
Tanaka Y, Abe Y, Oto Y, Itabashi H, Shiraishi M, Yoshino A, Obata K, Murakami N, Nagai T: Characterization of fat distribution in Prader-Willi syndrome: relationships with adipocytokines and influence of growth hormone treatment. Am J Med Genet A 2013;161A:27-33.
46.
Darendeliler F, Aycan Z, Cetinkaya E, Vidilisan S, Bas F, Bideci A, Demirel F, Darcan S, Buyukgebiz A, Yildiz M, Berberoglu M, Arslanoglu I, Bundak R: Effects of growth hormone on growth, insulin resistance and related hormones (ghrelin, leptin and adiponectin) in turner syndrome. Horm Res 2007;68:1-7.
47.
Willemsen RH, Mulder PG, van Toorenenbergen AW, Hokken-Koelega AC: Long-term GH treatment is not associated with disadvantageous changes of inflammatory markers and adipocytokines in children born small for gestational age. Clin Endocrinol 2008;68:198-205.
48.
Livingstone MB, Prentice AM, Coward WA, Strain JJ, Black AE, Davies PS, Stewart CM, McKenna PG, Whitehead RG: Validation of estimates of energy intake by weighed dietary record and diet history in children and adolescents. Am J Clin Nutr 1992;56:29-35.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.